- Research Methods &
- Research Training
- Research Into
|Title||Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Chiotos K, Vendetti N, Zaoutis TE, Baddley JW, Ostrosky-Zeichner L, Pappas P, Fisher BT|
|Journal||J Antimicrob Chemother|
|Date Published||2016 Dec|
|Keywords||Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidemia, Echinocandins, Fluconazole, Glucosyltransferases, Humans, Microbial Sensitivity Tests, Middle Aged, Propensity Score, Retrospective Studies, Survival Analysis, Treatment Outcome, Young Adult|
OBJECTIVES: A polymorphism in the gene encoding β-1,3-glucan synthase, the target of the echinocandin class of antifungals, results in increased in vitro MICs of the echinocandins. This has resulted in controversy surrounding use of the echinocandins for treatment of Candida parapsilosis candidaemia. We aimed to compare 30 day mortality in adults with C. parapsilosis candidaemia treated with echinocandins versus fluconazole.
METHODS: This is a retrospective observational cohort study. We used the Premier Perspective Database to identify adult patients with C. parapsilosis candidaemia treated with only fluconazole or only an echinocandin as definitive therapy. The primary outcome was 30 day mortality. Propensity scores were derived to estimate the probability the patient would have received either an echinocandin or fluconazole. Inverse probability of treatment weighting (IPTW) was used in a weighted logistic regression to calculate odds of 30 day mortality.
RESULTS: There were 307 unique patients with C. parapsilosis candidaemia. One hundred and twenty-six (41%) received fluconazole and 181 (59%) received an echinocandin. Age, gender, race, year of admission, need for ICU resources in the week prior to candidaemia onset, and receipt of vasopressors on the day of candidaemia onset were included in the propensity score model used to calculate inverse probability of treatment weights. Weighted logistic regression demonstrated no difference in 30 day mortality between patients receiving an echinocandin as compared with fluconazole (OR 0.82, 95% CI 0.33-2.07).
CONCLUSIONS: Our result supports the 2016 IDSA invasive candidiasis guidelines, which no longer clearly favour treatment with fluconazole over an echinocandin for C. parapsilosis candidaemia.
|Alternate Journal||J. Antimicrob. Chemother.|
|PubMed Central ID||PMC5181395|
|Grant List||T32 HD060550 / HD / NICHD NIH HHS / United States|